CN114246993A - Composite coating with adjustable active ingredient release performance and preparation method thereof - Google Patents
Composite coating with adjustable active ingredient release performance and preparation method thereof Download PDFInfo
- Publication number
- CN114246993A CN114246993A CN202111517486.2A CN202111517486A CN114246993A CN 114246993 A CN114246993 A CN 114246993A CN 202111517486 A CN202111517486 A CN 202111517486A CN 114246993 A CN114246993 A CN 114246993A
- Authority
- CN
- China
- Prior art keywords
- active ingredient
- composite coating
- release performance
- ingredient release
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 66
- 239000011248 coating agent Substances 0.000 title claims abstract description 60
- 239000004480 active ingredient Substances 0.000 title claims abstract description 50
- 239000002131 composite material Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000000758 substrate Substances 0.000 claims abstract description 25
- 239000011159 matrix material Substances 0.000 claims abstract description 18
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 238000005507 spraying Methods 0.000 claims abstract description 18
- 238000010285 flame spraying Methods 0.000 claims abstract description 17
- 239000011259 mixed solution Substances 0.000 claims abstract description 17
- 238000007788 roughening Methods 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 238000004140 cleaning Methods 0.000 claims abstract description 10
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims abstract description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 4
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 4
- 229940030225 antihemorrhagics Drugs 0.000 claims abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940127218 antiplatelet drug Drugs 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 239000002874 hemostatic agent Substances 0.000 claims abstract description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims abstract description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 4
- 230000002138 osteoinductive effect Effects 0.000 claims abstract description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims abstract description 3
- 238000005488 sandblasting Methods 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000007789 gas Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 239000004626 polylactic acid Substances 0.000 claims description 9
- -1 polyethylene Polymers 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 239000002737 fuel gas Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000004576 sand Substances 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims description 4
- 239000004812 Fluorinated ethylene propylene Substances 0.000 claims description 2
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000004642 Polyimide Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 229920006129 ethylene fluorinated ethylene propylene Polymers 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 239000004631 polybutylene succinate Substances 0.000 claims description 2
- 229920002961 polybutylene succinate Polymers 0.000 claims description 2
- 229920002530 polyetherether ketone Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 229920002379 silicone rubber Polymers 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000013329 compounding Methods 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000003746 surface roughness Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002861 polymer material Substances 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 3
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CVDADWBWFLWJNQ-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;hydrochloride Chemical compound Cl.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N CVDADWBWFLWJNQ-TWDWGCDDSA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- IUCXVORPVOMKHU-UHFFFAOYSA-N 1-[(3,6-dihydroxy-1-methyl-2,3-dihydroindol-5-yl)imino]guanidine Chemical compound CN1CC(C2=CC(=C(C=C21)O)N=NC(=N)N)O IUCXVORPVOMKHU-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229960004353 carbazochrome sodium sulfonate Drugs 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010041 electrostatic spinning Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- 150000002284 fumagillol derivatives Chemical class 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920013746 hydrophilic polyethylene oxide Polymers 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960004051 menadione sodium bisulfite Drugs 0.000 description 1
- XDPFHGWVCTXHDX-UHFFFAOYSA-M menadione sodium sulfonate Chemical compound [Na+].C1=CC=C2C(=O)C(C)(S([O-])(=O)=O)CC(=O)C2=C1 XDPFHGWVCTXHDX-UHFFFAOYSA-M 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940034049 polysaccharide-k Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229950003551 ramoplanin Drugs 0.000 description 1
- 108010076689 ramoplanin Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950005789 sarpogrelate Drugs 0.000 description 1
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HLFCZZKCHVSOAP-WXIWBVQFSA-M sodium;(5e)-5-(carbamoylhydrazinylidene)-1-methyl-6-oxo-2,3-dihydroindole-2-sulfonate Chemical compound [Na+].NC(=O)N\N=C/1C(=O)C=C2N(C)C(S([O-])(=O)=O)CC2=C\1 HLFCZZKCHVSOAP-WXIWBVQFSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-M sulfo sulfate Chemical compound OS(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 238000010345 tape casting Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N vitamin K3 Natural products C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
- B05D1/08—Flame spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/002—Pretreatement
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/24—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials for applying particular liquids or other fluent materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a preparation method of a composite coating with adjustable active ingredient release performance, which comprises the following steps: (1) preparing a mixed solution from at least two polymers and at least one active ingredient; (2) cleaning and roughening the surface of the matrix; (3) spraying the mixed solution obtained in the step (1) on the surface of the treated substrate by using a flame spraying process to prepare the composite coating with adjustable active ingredient release performance; the active ingredients comprise antibacterial agents, anticoagulants, antiplatelet drugs, angiogenesis inhibitors, hemostatic agents, antitumor agents, immunosuppressants and osteoinductive agents. The method has good repeatability, high safety and small influence on active ingredients, solves the problem that solvent systems among different macromolecules are difficult to construct, can combine the excellent characteristics of the different macromolecules, and the prepared composite coating with the adjustable release performance of the active ingredients can realize the release of the active ingredients at different rates.
Description
Technical Field
The invention relates to the technical field of composite coatings, in particular to a composite coating with adjustable active ingredient release performance and a preparation method thereof.
Background
The conventional medical materials have limited applications due to lack of antibacterial property, biological activity and osteoinductivity, so that surface functional modification is usually required. The polymer material has rich varieties, various mechanical properties, stable physical properties and different biocompatibility, so the polymer material is widely used for preparing the surface functionalized modified coating. However, because the slow release properties of different polymer coatings are very different and the solubility in different solvents is different, the conventional blending and compounding method after dissolution is severely restricted, and the release properties of a wide variety of polymer materials are difficult to be subjected to wide compound regulation and control. The flame spraying technology takes the polymer solution or suspension as the raw material to prepare the coating, is very suitable for preparing composite coatings of different polymer materials with larger performance difference, and has wide application prospect.
Chinese patent publication No. CN107286793A discloses a method for preparing a medical coating, comprising: uniformly mixing a reactant, a hydrophilic polymer and a proper amount of solvent according to a ratio to obtain a coating solution, and coating the coating solution on the surface of an object to be coated; and (4) drying by ultraviolet radiation, and forming a hydrophilic coating after the surface of the coated object is fully dried. The method is simple and easy to operate, the prepared medical coating has good bonding firmness with medical instruments and good lubricating effect, but the coating prepared by the coating solution coating method is easy to cause the problem of uneven coating.
Chinese patent publication No. CN110665070B discloses a method for preparing a medical coating with a hydrophilic lubricating surface, comprising: uniformly coating micelle coating liquid on the outer wall of the cleaned medical product by a dipping coating process, drying in vacuum to form a coating, and obtaining a hydrophilic lubricating medical coating on the surface of the medical product, wherein the micelle coating liquid contains poloxamer, hyaluronic acid or sodium salt thereof and a preservative. Due to the fact that the poloxamer has a hydrophobic polypropylene oxide chain segment and a hydrophilic polyethylene oxide chain segment, the coating is well combined with the surface of a medical appliance.
The Chinese patent document with the publication number of CN108815552B discloses a preparation method of a biomedical coating material with controllable loading and long-acting slow release of multiple drugs, which comprises the following steps: polishing, cleaning and drying a substrate material, soaking the substrate material in a dopamine solution, taking catechol-modified polyamino biomacromolecule, electronegative macromolecular solution and micelle loaded with various medicines as three components of layer-by-layer self-assembly, and preparing the coating modified material on the dopamine-treated substrate by using the three components through a layer-by-layer self-assembly method. The invention can realize the sustained release of a plurality of medicaments in a large time sequence, but the preparation method of the coating is complex.
Disclosure of Invention
The invention provides a preparation method of a composite coating with adjustable active ingredient release performance, which has the advantages of good repeatability, high safety and small influence on active ingredients, can be combined with the excellent characteristics of different macromolecules, solves the problem that solvent systems among different macromolecules are difficult to construct, and can realize the release of the active ingredients at different rates.
The technical scheme is as follows:
a preparation method of a composite coating with adjustable active ingredient release performance comprises the following steps:
(1) preparing a mixed solution from at least two polymers and at least one active ingredient;
(2) cleaning and roughening the surface of the matrix;
(3) spraying the mixed solution obtained in the step (1) on the surface of the treated substrate by using a flame spraying process to prepare the composite coating with adjustable active ingredient release performance;
the active ingredients comprise antibacterial agents, anticoagulants, antiplatelet drugs, angiogenesis inhibitors, hemostatic agents, antitumor agents, immunosuppressants and osteoinductive agents;
in the step (1), the solid content of the mixed solution is 3-50 g/100mL, and the mass ratio of the high polymer to the active ingredient is 2-1000: 1.
The adjustable release performance of the active ingredients refers to the regulation and control of the release performance of the composite coating by compounding different macromolecules or changing the compounding ratio.
In the step (1), the mixed solution is a polymer-active ingredient mixed solution or a polymer-active ingredient mixed suspension.
The polymer has excellent spraying characteristic, and comprises perfluoropropyl perfluorovinyl ether-polytetrafluoroethylene copolymer, ethylene-tetrafluoroethylene copolymer, fluorinated ethylene propylene copolymer, ethylene-fluorinated ethylene propylene copolymer, polyethylene, polypropylene, polyvinyl chloride, polyacrylate, silicone rubber, polyimide, polyether ether ketone, polyurethane, polylactic acid, polyglycolic acid, polylactic acid-glycolic acid copolymer, polycaprolactone, polyvinyl alcohol, polybutylene succinate or polyhydroxyalkanoate.
Preferably, the polymer particle size is 15-300 μm.
Preferably, the polymer is perfluoropropyl perfluorovinyl ether-polytetrafluoroethylene copolymer, ethylene-tetrafluoroethylene copolymer, polylactic acid or polycaprolactone.
The antibacterial agent includes but is not limited to copper and its compounds, silver and its compounds, povidone iodine, triclosan, chlorhexidine gluconate, chlorhexidine acetate, quaternary ammonium salts, gentamicin sulfate, gentamicin hydrochloride, amikacin sulfate, amikacin hydrochloride, tobramycin sulfate, tobramycin hydrochloride, clindamycin hydrochloride, lincosamide hydrochloride, moxifloxacin, ciprofloxacin, teicoplanin, vancomycin, ramoplanin, metronidazole, tinidazole or amitrazole.
The anticoagulant includes but is not limited to heparin, hirudin and its derivatives, argatroban, sodium citrate.
The antiplatelet drug includes but is not limited to sarpogrelate hydrochloride.
The angiogenesis inhibitor includes but is not limited to fumagillin, fumagillol derivatives or neogenesis inhibitory steroids.
Such hemostatic agents include, but are not limited to, thrombin, thromboplastin, acetyl menadione, menadione sodium bisulfite, tranexamic acid, epsilon-aminocaproic acid, adrenochrome monoaminoguanidine methyl sulfonate, or carbazochrome sodium sulfonate.
The antineoplastic agent comprises, but is not limited to, methotrexate, actinomycin D, mitomycin C, bleomycin hydrochloride, daunomycin hydrochloride, vinblastine sulfosulfate, aldehydic vinblastine sulfate, adriamycin, neocarzinostatin, fluorouracil, cytarabine, coriolus versicolor polysaccharide K, a streptococcus sanguis preparation, lentinan, betadine, levamisole, carbamyl cyanopyridine, glycyrrhizin, cisplatin or paclitaxel.
The immunosuppressant includes but is not limited to rapamycin, cyclosporine, tacrolimus, methotrexate, azathioprine, cyclophosphamide, dexamethasone or mizoribine.
The osteoinductive agent includes, but is not limited to, bone morphogenetic protein or fibroblast growth factor.
The solvent of the mixed solution comprises: acetone, tetrahydrofuran, dimethylformamide, ethanol or an aqueous solution of ethanol.
The substrate comprises metal, alloy, glass or plastic.
Preferably, in the step (2), the surface of the cleaned substrate is roughened by a sand blasting process, and the parameters of the sand blasting process are as follows: the air pressure is 0.5-1.0 MPa, the sand blasting time is 10 s-1 min, and the mesh number of sand pills for sand blasting is 30-200 meshes.
Preferably, in the step (3), the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure of 0.1-1 MPa and flow of 1-10 Nm3H; the fuel gas is C2H2Pressure 0.1-0.5 MPa, flow 1-5 Nm3H; the auxiliary gas is compressed air, and the pressure is 0.3-5.0 MPa; the spraying feeding speed is 10-100 g/min, and the spraying distance is 150-400 mm.
The invention also provides the composite coating with adjustable active ingredient release performance, which is prepared by the preparation method of the composite coating with adjustable active ingredient release performance.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention adopts the flame spraying technology to prepare the functional coating by compounding different macromolecules and active ingredients, overcomes the problems of larger solubility difference between different macromolecules and active ingredients and difficult construction of a solvent system compared with the electrostatic spinning technology and the tape casting technology, and ensures the safety of experimental operation.
(2) The method can be combined with the excellent characteristics of different macromolecules, such as elasticity, hardness, insulativity, conductivity and the like, and prepare the multifunctional composite coating with adjustable active ingredient release performance, which is suitable for different application scenes.
(3) The preparation method is simple, good in repeatability, small in influence on the active ingredients and suitable for large-scale application, and the prepared coating is a uniform and continuous coating and can effectively realize release of the active ingredients at different rates.
Detailed Description
The invention will be further elucidated with reference to the following examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1
(1) The method comprises the steps of adding 15g of polylactic acid (with the particle size of 30-100 mu m) and 5g of polycaprolactone (with the particle size of 15-55 mu m) into 200mL of 50% ethanol aqueous solution serving as a solvent to obtain a mixed polymer suspension, and adding 0.5g of gentamicin sulfate to prepare a mixed solution.
(2) Cleaning the surface of a substrate: the substrate is a stainless steel sheet, and is cleaned by acetone, alcohol and deionized water in sequence and then dried by nitrogen for later use; roughening the surface of the matrix: adopting a sand blasting process to carry out roughening treatment on the surface of the cleaned matrix so as to increase the surface roughness of the matrix and improve the bonding strength of the coating, wherein the parameters of the sand blasting process are as follows: the air pressure is 0.8MPa, the sand blasting time is 20s, and the mesh number of sand pills for sand blasting is 50 meshes;
(3) spraying the mixed liquid obtained in the step (1) on the surface of the treated substrate by using a flame spraying process, wherein the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure 0.5MPa, flow 2Nm3H; the fuel gas is C2H2Pressure 0.1MPa, flow 2Nm3H; the auxiliary gas is compressed air, the pressure is 0.8MPa, the feeding speed is 20g/min, and the spraying distance is 200mm, so that the composite coating with adjustable active ingredient release performance is prepared.
Example 2
(1) 200mL of 50% ethanol aqueous solution is used as a solvent, 5g of polylactic acid (with the particle size of 30-100 mu m) and 15g of polycaprolactone (with the particle size of 15-55 mu m) are added to obtain a mixed polymer suspension, and 0.5g of gentamicin sulfate is added to prepare a mixed solution.
(2) Cleaning the surface of a substrate: selecting glass as a substrate, sequentially cleaning the glass with acetone, alcohol and deionized water, and drying the glass with nitrogen for later use; roughening the surface of the matrix: adopting a sand blasting process to carry out roughening treatment on the surface of the cleaned matrix so as to increase the surface roughness of the matrix and improve the bonding strength of the coating, wherein the parameters of the sand blasting process are as follows: the air pressure is 0.8MPa, the sand blasting time is 20s, and the mesh number of sand pills for sand blasting is 50 meshes;
(3) spraying the mixed liquid obtained in the step (1) on the surface of the treated substrate by using a flame spraying process, wherein the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure 0.5MPa, flow 2Nm3H; the fuel gas is C2H2Pressure 0.1MPa, flow 2Nm3H; the auxiliary gas is compressed air, the pressure is 0.8MPa, the feeding speed is 20g/min, and the spraying distance is 200mm, so that the composite coating with adjustable active ingredient release performance is prepared.
Example 3
(1) 200mL of 50% ethanol aqueous solution is used as a solvent, 10g of polylactic acid (with the particle size of 30-100 mu m) and 10g of perfluoropropyl perfluorovinyl ether-polytetrafluoroethylene copolymer (with the particle size of 30-100 mu m) are added to obtain a mixed polymer suspension, and 0.5g of gentamicin sulfate is added to prepare a mixed solution.
(2) Cleaning the surface of a substrate: the substrate is a stainless steel sheet, and is cleaned by acetone, alcohol and deionized water in sequence and then dried by nitrogen for later use; roughening the surface of the matrix: adopting a sand blasting process to carry out roughening treatment on the surface of the cleaned matrix so as to increase the surface roughness of the matrix and improve the bonding strength of the coating, wherein the parameters of the sand blasting process are as follows: the air pressure is 0.8MPa, the sand blasting time is 20s, and the mesh number of sand pills for sand blasting is 50 meshes;
(3) spraying the mixed liquid obtained in the step (1) on the surface of the treated substrate by using a flame spraying process, wherein the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure 0.5MPa, flow 2Nm3H; the fuel gas is C2H2Pressure 0.1MPa, flow 2Nm3H; the auxiliary gas is compressed air, the pressure is 0.8MPa, the feeding speed is 15g/min, and the spraying distance is 150mm, so that the composite coating with the adjustable release performance of the active ingredients is prepared.
Example 4
(1) The method comprises the steps of adding 5g of polylactic acid (with the particle size of 30-100 mu m) and 15g of ethylene-tetrafluoroethylene copolymer (with the particle size of 30-100 mu m) into 200mL of 70% ethanol aqueous solution serving as a solvent to obtain a mixed polymer suspension, and adding 0.5g of chlorhexidine gluconate to prepare a mixed solution.
(2) Cleaning the surface of a substrate: the substrate is a stainless steel sheet, and is cleaned by acetone, alcohol and deionized water in sequence and then dried by nitrogen for later use; roughening the surface of the matrix: adopting a sand blasting process to carry out roughening treatment on the surface of the cleaned matrix so as to increase the surface roughness of the matrix and improve the bonding strength of the coating, wherein the parameters of the sand blasting process are as follows: the air pressure is 0.8MPa, the sand blasting time is 30s, and the mesh number of sand pills for sand blasting is 100 meshes;
(3) spraying the mixed liquid obtained in the step (1) on the surface of the treated substrate by using a flame spraying process, wherein the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure 0.5MPa, flow 2Nm3H; the fuel gas is C2H2Pressure 0.1MPa, flow 2Nm3H; the auxiliary gas is compressed air, the pressure is 0.8MPa, the feeding speed is 15g/min, and the spraying distance is 150mm, so that the composite coating with the adjustable release performance of the active ingredients is prepared.
Example 5
(1) The method comprises the steps of adding 15g of polylactic acid (with the particle size of 30-100 mu m) and 5g of ethylene-tetrafluoroethylene copolymer (with the particle size of 30-100 mu m) into 200mL of 70% ethanol aqueous solution serving as a solvent to obtain a mixed polymer suspension, and adding 0.5g of chlorhexidine gluconate to prepare a mixed solution.
(2) Cleaning the surface of a substrate: the substrate is a stainless steel sheet, and is cleaned by acetone, alcohol and deionized water in sequence and then dried by nitrogen for later use; roughening the surface of the matrix: adopting a sand blasting process to carry out roughening treatment on the surface of the cleaned matrix so as to increase the surface roughness of the matrix and improve the bonding strength of the coating, wherein the parameters of the sand blasting process are as follows: the air pressure is 0.8MPa, the sand blasting time is 30s, and the mesh number of sand pills for sand blasting is 100 meshes;
(3) spraying the mixed liquid obtained in the step (1) on the surface of the treated substrate by using a flame spraying process, wherein the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure 0.5MPa, flow 2Nm3H; the fuel gas is C2H2Pressure 0.1MPa, flow 2Nm3H; the auxiliary gas is compressed air, the pressure is 0.8MPa, the feeding speed is 15g/min, and the spraying distance is 150mm, so that the composite coating with the adjustable release performance of the active ingredients is prepared.
Sample analysis
The coating samples (2cm × 2cm) of examples 1 to 5 were soaked in 5mL of PBS solution after the side and bottom surfaces were closed with hot melt adhesive, and the amount of active ingredient released after 4 hours was measured, and the results are shown in table 1:
TABLE 1 active ingredient Release Performance of composite coatings in examples 1-5
Sample (I) | Release concentration in soak solution (mg/L) |
Example 1 | 15.6 |
Example 2 | 4.2 |
Example 3 | 9.3 |
Example 4 | 2.8 |
Example 5 | 12.5 |
As can be seen from the data in Table 1, the release performance of the active ingredient of the prepared composite coating can be effectively regulated and controlled by compounding different macromolecules or changing the compounding ratio.
The embodiments described above are intended to illustrate the technical solutions of the present invention in detail, and it should be understood that the above-mentioned embodiments are only specific embodiments of the present invention, and are not intended to limit the present invention, and any modification, supplement or similar substitution made within the scope of the principles of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. The preparation method of the composite coating with adjustable active ingredient release performance is characterized by comprising the following steps:
(1) preparing a mixed solution from at least two polymers and at least one active ingredient;
(2) cleaning and roughening the surface of the matrix;
(3) spraying the mixed solution obtained in the step (1) on the surface of the treated substrate by using a flame spraying process to prepare the composite coating with adjustable active ingredient release performance;
the active ingredients comprise antibacterial agents, anticoagulants, antiplatelet drugs, angiogenesis inhibitors, hemostatic agents, antitumor agents, immunosuppressants and osteoinductive agents;
in the step (1), the solid content of the mixed solution is 3-50 g/100mL, and the mass ratio of the high polymer to the active ingredient is 2-1000: 1.
2. The method for preparing a composite coating with adjustable active ingredient release performance according to claim 1, wherein the polymer comprises perfluoropropyl perfluorovinyl ether-polytetrafluoroethylene copolymer, ethylene-tetrafluoroethylene copolymer, fluorinated ethylene propylene copolymer, ethylene-fluorinated ethylene propylene copolymer, polyethylene, polypropylene, polyvinyl chloride, polyacrylate, silicone rubber, polyimide, polyether ether ketone, polyurethane, polylactic acid, polyglycolic acid, polylactic acid-glycolic acid copolymer, polycaprolactone, polyvinyl alcohol, polybutylene succinate, or polyhydroxyalkanoate.
3. The method for preparing the composite coating with the adjustable active ingredient release performance according to claim 1, wherein the particle size of the polymer is 15-300 μm.
4. The method for preparing the composite coating with adjustable active ingredient release performance according to claim 1, wherein the polymer is perfluoropropyl perfluorovinyl ether-polytetrafluoroethylene copolymer, ethylene-tetrafluoroethylene copolymer, polylactic acid or polycaprolactone.
5. The method for preparing a composite coating with adjustable active ingredient release performance according to claim 1, wherein the solvent of the mixed solution comprises: acetone, tetrahydrofuran, dimethylformamide, ethanol or an aqueous solution of ethanol.
6. The method for preparing a composite coating with adjustable active ingredient release property according to claim 1, wherein the substrate comprises metal, alloy, glass or plastic.
7. The method for preparing the composite coating with adjustable active ingredient release performance according to claim 1, wherein in the step (2), the surface of the cleaned substrate is roughened by a sand blasting process, and the parameters of the sand blasting process are as follows: the air pressure is 0.5-1.0 MPa, the sand blasting time is 10 s-1 min, and the mesh number of sand pills for sand blasting is 30-200 meshes.
8. The method for preparing the composite coating with adjustable active ingredient release performance according to claim 1, wherein in the step (3), the flame spraying conditions are as follows: the combustion-supporting gas is O2Pressure of 0.1-1 MPa and flow of 1-10 Nm3H; the fuel gas is C2H2Pressure 0.1-0.5 MPa, flow 1-5 Nm3H; the auxiliary gas is compressed air, and the pressure is 0.3-5.0 MPa; the spraying feeding speed is 10-100 g/min, and the spraying distance is 150-400 mm.
9. The composite coating with adjustable active ingredient release performance prepared by the preparation method of the composite coating with adjustable active ingredient release performance according to any one of claims 1 to 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111517486.2A CN114246993B (en) | 2021-12-09 | 2021-12-09 | Composite coating with adjustable active ingredient release performance and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111517486.2A CN114246993B (en) | 2021-12-09 | 2021-12-09 | Composite coating with adjustable active ingredient release performance and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114246993A true CN114246993A (en) | 2022-03-29 |
CN114246993B CN114246993B (en) | 2023-09-01 |
Family
ID=80792065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111517486.2A Active CN114246993B (en) | 2021-12-09 | 2021-12-09 | Composite coating with adjustable active ingredient release performance and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114246993B (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040070875A (en) * | 2003-02-05 | 2004-08-11 | 학교법인 인하학원 | Method for coating bioactive glasses on alumina plate |
CN1791437A (en) * | 2003-05-16 | 2006-06-21 | 布卢薄膜有限责任公司 | Medical implants comprising biocompatible coatings |
CN101214396A (en) * | 2008-01-03 | 2008-07-09 | 乐普(北京)医疗器械股份有限公司 | Controlled degradation magnesium alloy coating bracket and preparation thereof |
WO2010130109A1 (en) * | 2009-05-12 | 2010-11-18 | 四川大学 | Method for preparing porous hydroxyapatite coatings by suspension plasma spraying |
US20110300188A1 (en) * | 2010-06-02 | 2011-12-08 | Shimp Lawrence A | Glassy calcium phosphate particulates, coatings and related bone graft materials |
CN105838239A (en) * | 2016-04-13 | 2016-08-10 | 中国科学院宁波材料技术与工程研究所 | Polyimide composite coating and preparation method thereof and application thereof |
CN106139259A (en) * | 2016-08-17 | 2016-11-23 | 林春梅 | One has drug slow release function blood vessel bracket coating and preparation method thereof |
CN106267378A (en) * | 2016-10-10 | 2017-01-04 | 同济大学 | A kind of preparation method of the metal rack of controlled degradation |
CN109136814A (en) * | 2018-08-20 | 2019-01-04 | 陕西鑫威泰生物科技有限公司 | A kind of preparation method customizing skull board for pillow polyether-ether-ketone composite coating |
CN109457207A (en) * | 2018-11-22 | 2019-03-12 | 九江学院 | A kind of preparation method of hydroxylapatite-magnesium composite coating |
CN111658798A (en) * | 2020-06-15 | 2020-09-15 | 安徽静斯德科技有限公司 | Mask disinfection and sterilization method based on plasma |
EP3834853A1 (en) * | 2019-12-13 | 2021-06-16 | EMPA Eidgenössische Materialprüfungs- und Forschungsanstalt | Coatings, coated implants and manufacturing methods therefore |
-
2021
- 2021-12-09 CN CN202111517486.2A patent/CN114246993B/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040070875A (en) * | 2003-02-05 | 2004-08-11 | 학교법인 인하학원 | Method for coating bioactive glasses on alumina plate |
CN1791437A (en) * | 2003-05-16 | 2006-06-21 | 布卢薄膜有限责任公司 | Medical implants comprising biocompatible coatings |
CN101214396A (en) * | 2008-01-03 | 2008-07-09 | 乐普(北京)医疗器械股份有限公司 | Controlled degradation magnesium alloy coating bracket and preparation thereof |
WO2010130109A1 (en) * | 2009-05-12 | 2010-11-18 | 四川大学 | Method for preparing porous hydroxyapatite coatings by suspension plasma spraying |
US20110300188A1 (en) * | 2010-06-02 | 2011-12-08 | Shimp Lawrence A | Glassy calcium phosphate particulates, coatings and related bone graft materials |
CN105838239A (en) * | 2016-04-13 | 2016-08-10 | 中国科学院宁波材料技术与工程研究所 | Polyimide composite coating and preparation method thereof and application thereof |
CN106139259A (en) * | 2016-08-17 | 2016-11-23 | 林春梅 | One has drug slow release function blood vessel bracket coating and preparation method thereof |
CN106267378A (en) * | 2016-10-10 | 2017-01-04 | 同济大学 | A kind of preparation method of the metal rack of controlled degradation |
CN109136814A (en) * | 2018-08-20 | 2019-01-04 | 陕西鑫威泰生物科技有限公司 | A kind of preparation method customizing skull board for pillow polyether-ether-ketone composite coating |
CN109457207A (en) * | 2018-11-22 | 2019-03-12 | 九江学院 | A kind of preparation method of hydroxylapatite-magnesium composite coating |
EP3834853A1 (en) * | 2019-12-13 | 2021-06-16 | EMPA Eidgenössische Materialprüfungs- und Forschungsanstalt | Coatings, coated implants and manufacturing methods therefore |
CN111658798A (en) * | 2020-06-15 | 2020-09-15 | 安徽静斯德科技有限公司 | Mask disinfection and sterilization method based on plasma |
Non-Patent Citations (2)
Title |
---|
A.CHEBBI等: "《Thermal Spraying of Bioactive Polymer Coatings for Orthopaedic Applications》", 《JOURNAL OF THERMAL SPRAY TECHNOLOGY》, vol. 21, no. 3, pages 719 - 730 * |
YONGHONG PAN 等: "《Facile suspension flame spray fabrication of polylactic acid-povidone-iodine coatings for antimicrobial applications》", 《MATERIALS LETTERS》, vol. 341, pages 134293 * |
Also Published As
Publication number | Publication date |
---|---|
CN114246993B (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104189963B (en) | Reduction can the preparation method of surface coating of degradable magnesium alloy blood vessel rack degradation rate | |
Cui et al. | Preparation of hydrophilic poly (L-lactide) electrospun fibrous scaffolds modified with chitosan for enhanced cell biocompatibility | |
JP4526851B2 (en) | Polysaccharide nanoscale fibers and compacts | |
JP6817472B2 (en) | Pharmaceutical compositions and coatings | |
JP6738833B2 (en) | Antibacterial nanofiber | |
EP2708356A1 (en) | Thin film with base and method for producing same | |
Francolini et al. | Synthesis of biomimetic segmented polyurethanes as antifouling biomaterials | |
Li et al. | Silk fibroin/polycaprolactone-polyvinyl alcohol directional moisture transport composite film loaded with antibacterial drug-loading microspheres for wound dressing materials | |
Egghe et al. | Substrate-independent and widely applicable deposition of antibacterial coatings | |
Yu et al. | Preparation of multifunctional poly (l-lactic acid) film using heparin-mimetic polysaccharide multilayers: Hemocompatibility, cytotoxicity, antibacterial and drug loading/releasing properties | |
Mihailescu et al. | Gradient multifunctional biopolymer thin film assemblies synthesized by combinatorial MAPLE | |
CN102671240A (en) | Method for preparing multifunctional antibacterial chitosan stable gel coat | |
Guo et al. | Tyramine-enhanced zwitterion hyaluronan hydrogel coating for anti-fouling and anti-thrombosis | |
Wang et al. | 3D printing of multi-functional artificial conduits against acute thrombosis and clinical infection | |
Zhang et al. | A multifunctional coating with silk fibroin/chitosan quaternary ammonium salt/heparin sodium for AZ31B magnesium alloy | |
CN1764482B (en) | Vascular stent | |
CN114246993B (en) | Composite coating with adjustable active ingredient release performance and preparation method thereof | |
Rahvar et al. | Micro/nanoscale surface engineering to enhance hemocompatibility and reduce bacterial adhesion for cardiovascular implants | |
KR20180034848A (en) | Hydrophilic medical catheter and manufacturing method thereof | |
Lenzuni et al. | Electrosprayed zein nanoparticles as antibacterial and anti-thrombotic coatings for ureteral stents | |
Park et al. | Blood-compatible and biodegradable polymer-coated drug-eluting stent | |
KR20100088452A (en) | Nanofiber nonwoven fabric having chitosan layer and manufacturing method thereof | |
EP1644054B1 (en) | Coating system for implants for increasing tissue compatibility | |
Gozutok et al. | Development of antibacterial composite electrospun chitosan-coated polypropylene materials | |
KR101982400B1 (en) | Development of polysaccharide based antimicrobial coating technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |